Core Insights - NewGenIvf Group Limited has entered a binding term sheet with White Lion Capital LLC for a Digital Assets Purchase Agreement involving 600,000 Solana (SOL) tokens [1][2] - The agreement allows NewGen to sell shares of common stock to White Lion over a 24-month period, receiving compensation in Solana tokens instead of cash, aligning with the company's Solana treasury strategy [2][4] - NewGen's digital asset strategy was launched in December 2024, with an initial investment of US$1 million, and has since established a Solana treasury and engaged in real-world asset tokenization projects [4] Company Overview - NewGenIvf Group is a diversified, tech-forward entity focusing on real estate development, digital asset management, and reproductive health solutions [5] - The company operates through three divisions: NewGenProperty (real estate), NewGenDigital (digital assets and DeFi), and NewGenSup (health and longevity products) [5] - NewGen has accumulated 13,000 Solana tokens valued at approximately US$2.5 million as of the press release date [4]

Core Insights - NewGenIvf Group Limited has signed an engagement letter with World Chinese Museum to act as the worldwide agent for the tokenization of the Client's high-value private art collection [1][2][3] - The initial tranche of artwork to be tokenized is valued at US$2 million, with potential expansion up to US$200 million based on the success of the initial rollout [3] - NewGen will earn a 15% fee on the total value of the tokenized assets, creating a new revenue stream for the Company [3] - The art tokenization market is rapidly growing, providing liquidity and fractional ownership opportunities for investors [4] - The CEO of NewGen emphasized the strategic importance of this initiative in the decentralized finance landscape and highlighted the potential disruption in the art market through blockchain technology [5] Company Overview - NewGenIVF Group operates in three strategic business divisions: NewGenProperty (real estate development), NewGenDigital (digital asset and DeFi solutions), and NewGenSup (health and longevity products) [6] - The Company is positioned to capitalize on emerging opportunities across real estate, healthcare, and digital assets, leveraging technology for sustainable growth [6]

As filed with the Securities and Exchange Commission on October 10, 2025 Registration No. 333-290284 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Amendment No. 1 to Form F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NEWGENIVF GROUP LIMITED (Exact name of registrant as specified in its charter) British Virgin Islands 8090 Not Applicable (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Wing Fung Alfre ...

Core Viewpoint - NewGenIVF Group Limited has been initiated for equity research coverage by Zacks Small-Cap Research, highlighting its potential in various high-growth sectors [1]. Group 1: Company Overview - NewGenIVF Group is a diversified, tech-forward entity focusing on real estate development, digital asset management, and reproductive health solutions [2]. - The company operates through three strategic divisions: NewGenProperty (real estate in UAE), NewGenDigital (digital asset and DeFi solutions), and NewGenSup (health and longevity products) [2]. - NewGenIVF Group has a legacy in providing IVF and assisted reproductive treatment services across Asia, positioning it uniquely in the market [2]. Group 2: Market Positioning - The company leverages cutting-edge technology and innovative solutions to drive sustainable growth and high returns on investment for shareholders [2]. - NewGenIVF Group is strategically positioned to capitalize on the convergence of real estate, healthcare, and digital asset opportunities in the evolving global economy [2].

Exhibit 99.1 NEWGENIVF GROUP LIMITED AND SUBSIDIARIES INDEX TO UNAUDITED CONDENSE CONSOLIDATED FINANCIAL STATEMENTS | Unaudited consolidated statements of financial position as of June 30, 2024, and December 31, 2024 | F-2 | | --- | --- | | Unaudited consolidated statements of profit or loss and other comprehensive income for the six months ended June 30, | F-3 | | 2025 and 2024 | | | Notes to the unaudited consolidated statements of profit or loss and other comprehensive income | F-4 | F-1 NEWGENIVF GROUP ...

Core Insights - NewGen has established a joint venture with BNW to develop a strategic plot of land in Ras Al Khaimah's Beach District, UAE, marking a significant step in its diversification strategy [1][2] - The feasibility study indicates potential net returns of up to US$67 million for NewGen, representing a 272% return on investment [3][4] - NewGen will hold a 60% stake in the joint venture, while BNW will manage construction and associated costs, minimizing NewGen's initial capital requirements [1][4][5] Financial Projections - The project is expected to complete by 2028, with a projected sale price of approximately US$817 per square foot and a total saleable area of 527,753 square feet [3] - The revenue potential from this project signifies a fundamental shift in NewGen's business focus, providing substantial non-dilutive capital for further strategic expansion [4][5] Strategic Advantages - The joint venture diversifies NewGen's revenue streams and reduces dependence on a single sector, enhancing its presence in the UAE real estate market [5][6] - The project targets high-net-worth mainland Chinese buyers, leveraging NewGen's established presence in Asia and the UAE's Golden Visa Program to attract international investors [6] Partnership Dynamics - BNW, a prominent real estate developer with a portfolio valued at approximately US$6 billion, will bear all construction and management costs, allowing NewGen to focus on maximizing returns [6][9] - The partnership is seen as a strategic milestone for both companies, aiming to unlock unique asset classes with strong demand fundamentals [7][8]

Core Insights - NewGenIvf Group Limited has received a valuation report from a Big Four global accounting firm, setting the fair value of its recently acquired advanced cytometry intellectual property at US$17.9 million, which boosts the company's net asset value (NAV) per share by approximately US$8.9 [1][2] - The acquisition marks a strategic shift for NewGen from traditional IVF services to a technology-driven model, aiming to generate high-margin, recurring revenue through licensing and supplying proprietary consumables [2][4] - NewGen is pursuing regulatory approvals to commercialize the technology and plans to establish an in-house R&D team to maintain its competitive edge in the growing fertility services market, particularly in the Asia Pacific region [3][4] Company Strategy - The acquisition of advanced cytometry technology positions NewGen as a technology leader in the fertility services industry, allowing it to provide exclusive, technology-backed solutions to partner clinics without requiring upfront investments [2][4] - The company aims to create a sustainable growth model through royalty-based revenue streams, enhancing its operational capabilities and unlocking immediate value for shareholders [4] Market Context - The global fertility services market is experiencing significant growth, with 1 in 6 couples worldwide affected by infertility, presenting a substantial opportunity for NewGen to capture market share [3]

As filed with the Securities and Exchange Commission on September 18, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NEWGENIVF GROUP LIMITED (Exact name of registrant as specified in its charter) British Virgin Islands 8090 Not Applicable (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number ...

As filed with the Securities and Exchange Commission on September 15, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form F-1 Wing Fung Alfred Siu Chief Executive Officer 36/39-36/40, 13th Floor, PS Tower Sukhumvit 21 Road (Asoke) Khlong Toei Nuea Sub-district Watthana District, Bangkok 10110 Thailand Tel: +1 (212) 537-4406 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NEWGENIVF GROUP LIMITED (Exact name of registrant as specified in its charter) B ...

Core Insights - NewGen has acquired advanced cytometry technology and assets, including 18 fully-constructed cell-sorting systems and six related patents, to enhance its market position and support U.S. expansion [1][2][4] - The U.S. fertility services market is growing, with over 432,000 IVF cycles performed in 2023, indicating a significant opportunity for NewGen's NewGenSort services [3][5] Company Developments - The acquisition builds on NewGen's earlier purchase of MicroSort technology, now rebranded as NewGenSort, which allows for precise separation of sperm cells based on chromosomal content [2][5] - NewGen anticipates that its U.S. operations could generate over $20 million in annual gross revenue once fully operational, based on conservative pricing and utilization assumptions [4] Market Context - The Society for Assisted Reproductive Technology reported an increase in IVF cycles from 389,993 in 2022 to 432,641 in 2023, with IVF births rising from 91,771 to 95,860 during the same period [3] - Each sorting system is projected to perform around four sorts per day, allowing NewGen to process over 25,000 sorts annually, which represents less than 6% of total U.S. IVF cycles [3][4] Strategic Vision - The CEO of NewGen emphasized that this acquisition is a significant milestone in the company's expansion strategy, aimed at meeting the growing demand for advanced fertility services in the U.S. market [5]